THIRD TEAM Marc Goodman UBS
Marc Goodman lands in third place for a second straight year — and for the third time in four years. The UBS analyst upgraded Watson Pharmaceuticals of Parsippany, New Jersey, from hold to buy in November, at $50.36, after the company reached an agreement with Johnson & Johnson to market a generic version of the latter’s Concerta medication, which is used to treat attention deficit hyperactivity disorder. Under the terms of the deal, Watson will distribute the drug and New Brunswick, New Jersey–based Johnson & Johnson will receive a share of the revenue through 2014. Watson’s shares had leaped 33.3 percent by the end of August, to $67.12, and jumped past the sector by 30.6 percentage points.